enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings Inc. (Nasdaq: ENGN) has reported the grant of inducement equity awards to seven newly-hired employees on September 30, 2024. The awards consist of non-qualified stock options to purchase a total of 183,000 common shares at an exercise price of $6.60 per share, equal to the closing price on the grant date. Each option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. The grants were made by the Company's independent Compensation Committee as an inducement for employment, in accordance with NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) ha annunciato la concessione di premi azionari di indennizzo a sette nuovi assunti il 30 settembre 2024. I premi consistono in opzioni su azioni non qualificate per l'acquisto di un totale di 183.000 azioni ordinarie a un prezzo di esercizio di 6,60 dollari per azione, pari al prezzo di chiusura nel giorno della concessione. Ogni opzione ha un termine di 10 anni e maturerà nel corso di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi tre anni. Le concessioni sono state effettuate dal Comitato Compensazione indipendente della Società come indennizzo per l'impiego, in conformità con NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) ha reportado la concesión de premios de acciones de inducción a siete nuevos empleados contratados el 30 de septiembre de 2024. Los premios consisten en opciones sobre acciones no calificadas para comprar un total de 183,000 acciones ordinarias a un precio de ejercicio de $6.60 por acción, igual al precio de cierre en la fecha de concesión. Cada opción tiene un plazo de 10 años y se vestirá durante cuatro años, con el 25% acreditándose después de un año y el resto acreditándose mensualmente durante los tres años siguientes. Las concesiones fueron realizadas por el Comité de Compensación independiente de la Compañía como incentivo para el empleo, de acuerdo con NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN)는 2024년 9월 30일에 새로 고용된 7명의 직원에게 유인성 주식 보상을 부여했다고 보고했습니다. 이 보상은 비자격 주식 옵션으로, 총 183,000주 일반 주식을 주당 6.60달러에 구매할 수 있는 권리를 포함합니다. 이는 부여일의 종가와 동일합니다. 각 옵션의 유효기간은 10년이며, 4년 동안 점진적으로 부여됩니다. 첫 해에 25%가 부여되고 나머지는 이후 3년 동안 월별로 부여됩니다. 이 보상은 회사의 독립 보상 위원회에 의해 고용 유인을 위해 제공되었으며, NASDAQ Listing Rule 5635(c)(4)에 따라 이루어졌습니다.
enGene Holdings Inc. (Nasdaq: ENGN) a rapporté la concession de récompenses en actions d'incitation à sept nouveaux employés le 30 septembre 2024. Les récompenses se composent de stock-options non qualifiées pour l'achat d'un total de 183 000 actions ordinaires à un prix d'exercice de 6,60 $ par action, égal au prix de clôture à la date de concession. Chaque option a une durée de 10 ans et sera acquise sur quatre ans, avec 25 % acquérant après un an et le reste s'acquérant mensuellement au cours des trois années suivantes. Les concessions ont été effectuées par le Comité de rémunération indépendant de l'entreprise comme incitation à l'emploi, conformément à NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) hat am 30. September 2024 die Gewährung von Anreizaktien an sieben neu eingestellte Mitarbeiter gemeldet. Die Auszeichnungen bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von insgesamt 183.000 Stammaktien zu einem Ausübungspreis von 6,60 US-Dollar pro Aktie, was dem Schlusskurs am Tag der Gewährung entspricht. Jede Option hat eine Laufzeit von 10 Jahren und wird über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und der Rest monatlich über die folgenden drei Jahre fällig wird. Die Gewährungen wurden vom unabhängigen Vergütungsausschuss des Unternehmens als Anreiz für die Beschäftigung gewährt, gemäß NASDAQ Listing Rule 5635(c)(4).
- Attraction of new talent with stock options as incentives
- Alignment of employee interests with company performance through equity awards
- Potential dilution of existing shareholders' equity
The inducement awards consist of a non-qualified stock options to purchase an aggregate 183,000 of the Company's common shares. The options each have an exercise price of
The stock options were granted by the Company's independent Compensation Committee of the Board of Directors as an inducement material to each new employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). While the stock options were granted outside of the Company’s Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, each option will have terms and conditions consistent with those set forth under the Plan.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001973495/en/
For media contact: media@engene.com
For investor contact: investors@engene.com
Source: enGene Holdings Inc.
FAQ
How many new employees received stock options from enGene Holdings Inc. (ENGN) on September 30, 2024?
What is the exercise price of the stock options granted by enGene Holdings Inc. (ENGN) on September 30, 2024?
How many common shares can be purchased with the stock options granted by enGene Holdings Inc. (ENGN) on September 30, 2024?
What is the vesting schedule for the stock options granted by enGene Holdings Inc. (ENGN) on September 30, 2024?
